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Abstract
Introduction Microarray-based gene expression profiling
represents a major breakthrough for understanding the
molecular complexity of breast cancer. cDNA expression
profiles cannot detect changes in activities that arise from post-
translational modifications, however, and therefore do not
provide a complete picture of all biologically important changes
that occur in tumors. Additional opportunities to identify and/or
validate molecular signatures of breast carcinomas are provided
by proteomic approaches. Surface-enhanced laser desorption/
ionization time-of-flight mass spectrometry (SELDI-TOF MS)
offers high-throughput protein profiling, leading to extraction of
protein array data, calling for effective and appropriate use of
bioinformatics and statistical tools.
Methods Whole tissue lysates of 105 breast carcinomas were
analyzed on IMAC 30 ProteinChip Arrays (Bio-Rad, Hercules,
CA, USA) using the ProteinChip Reader Model PBS IIc (Bio-
Rad) and Ciphergen ProteinChip software (Bio-Rad, Hercules,
CA, USA). Cluster analysis of protein spectra was performed to
identify protein patterns potentially related to established
clinicopathological variables and/or tumor markers.
Results Unsupervised hierarchical clustering of 130 peaks
detected in spectra from breast cancer tissue lysates provided
six clusters of peaks and five groups of patients differing
significantly in tumor type, nuclear grade, presence of hormonal
receptors, mucin 1 and cytokeratin 5/6 or cytokeratin 14. These
tumor groups resembled closely luminal types A and B, basal
and HER2-like carcinomas.
Conclusion Our results show similar clustering of tumors to
those provided by cDNA expression profiles of breast
carcinomas. This fact testifies the validity of the SELDI-TOF MS
proteomic approach in such a type of study. As SELDI-TOF MS
provides different information from cDNA expression profiles,
the results suggest the technique's potential to supplement and
expand our knowledge of breast cancer, to identify novel
biomarkers and to produce clinically useful classifications of
breast carcinomas.
Introduction
Extensive progress has been achieved towards understanding
the epidemiology, clinical course, and basic biology of breast
cancer. Several clinicopathologic factors – such as tumor
grade, anatomical extent, presence/absence of lymph node
metastases, presence of hormonal receptors and HER2/neu
oncogene amplification – have been recognized as having
prognostic and predictive value, influencing the management
of patients suffering from breast cancer.
Microarray-based gene expression profiling represents
another major breakthrough in the understanding of the
ER = estrogen receptor; HPLC = high-performance liquid chromatography; SELDI-TOF MS = surface-enhanced laser desorption/ionization time-of-
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molecular complexity of breast cancer [1,2]. Gene expression
signatures have been identified that are associated with the
presence of hormonal receptors, tumor grade and ability to
metastasize [3-6]. These approaches can also identify gene
expression signatures that predict response to specific chem-
otherapies or hormone-based therapies [7,8]. cDNA expres-
sion profiles cannot detect changes in activities that arise from
post-translational modifications, however, and therefore do not
provide a complete picture of all biologically important
changes that occur in tumors.
Additional opportunities to identify and/or validate molecular
signatures of breast carcinomas are provided by high-through-
put proteomic approaches. Tissue microarrays represent the
most developed high-throughput proteomic technology used
to refine our knowledge of breast carcinoma. Immunohisto-
chemical studies in tissue microarrays have confirmed the
results of cDNA expression profiling and have identified iden-
tical breast carcinoma phenotypes; that is, two hormonal
receptor-positive groups with luminal epithelial differentiation,
a group with dominant HER2/neu expression, and a group
with basal epithelial characteristics [9].
Hierarchical clustering of protein profiles obtained by immuno-
histochemistry also exhibits prognostic significance [10]. As
immunohistochemical studies are able to evaluate only those
proteins already described, another approach is necessary to
identify novel proteins not yet associated with tumor clinico-
pathological characteristics. Surface-enhanced laser desorp-
tion/ionization time-of-flight mass spectrometry (SELDI-TOF
MS) represents a high-throughput proteomic platform suitable
for these types of study. SELDI-TOF MS is based on the sur-
face capture of proteins or peptides from a biologic sample
using defined chemical interactions with a solid surface [11].
The specific detection of ionized protein molecules is based
on time-of-flight mass spectrometry.
The development of SELDI-TOF MS has overcome limitations
of other proteomic approaches in terms of the inability to ana-
lyze hundreds of samples within a short time [12], which is
essential for obtaining biologically and statistically relevant
data in medical proteomic research. In addition, SELDI-TOF
MS requires several times less starting material in comparison
with two-dimensional polyacrylamide gel electrophoresis [13].
SELDI-TOF MS thus offers high-throughput protein profiling,
leading to extraction of protein array data, which are often
characterized by a large number of variables (the mass peaks),
calling for effective and appropriate use of bioinformatics and
statistical tools.
SELDI-TOF MS has been used to generate protein profiles of
several cancer types, including breast cancer, to discriminate
between malignant tumors and nonmalignant tumors with
good sensitivity and specificity [14-17]. The majority of studies
have analyzed body fluid samples such as serum [18], nipple
aspirate fluid [14,19], or ductal lavage fluid [20]. Ricolleau and
colleagues detected two prognostic biomarkers, ubiquitin and
ferritin light chain, in node-negative breast cancer tumors [21].
Nakagawa and colleagues identified differences in the protein
profiles of microdissected primary breast cancer tissue sam-
ples with and without axillary lymph node metastasis [17].
The aim of the present study was to evaluate tissue lysates of
breast cancers by SELDI-TOF MS to identify protein patterns
related to clinicopathological variables and/or tumor markers.
To reveal similar protein expression profiles within 105
patients, unsupervised hierarchical clustering with a distance
measure based on Spearman correlation and the Ward
method of linkage of clusters was applied both to protein pat-
terns (to reveal subgroups of patients) and to peaks (to reveal
groups of peaks). The data show that this high-throughput pro-
tein profiling technique identifies patterns of expression that
discriminate different types of breast tumors that group
according to clinicopathological variables, and provides simi-
lar classification groups to cDNA expression profiling.
Materials and methods
Patient selection and characterization of specimens
Breast carcinomas of 105 female patients treated at the Masa-
ryk Memorial Cancer Institute (Brno, Czech Republic) in 2004
and 2005 were collected from surgically treated women with-
out neoadjuvant treatment and clinically documented distant
metastases. Informed consent confirming the availability of
redundant tissue samples for research use was obtained from
each participating subject.
The main clinicopathological variables – including tumor type,
grade and nuclear grade according to Elston and Ellis [22],
and estrogen receptor (ER), progesterone receptor and
HER2/neu status – were extracted from pathological records.
Additional immunohistochemistry and fluorescence in situ
hybridization were performed in tissue microarrays to estimate
cyclin D1 overexpression and amplification, the presence of
cytokeratin 5/6 and cytokeratin 14, mucin 1 and gross cystic
fluid protein.
Information about the antibodies, probes and protocols
applied is presented in Table 1. In our set of samples, the pT2
(57 cases, 54%) and pT3 (6 cases, 6%) tumors predominated
above pT1 tumors (42 cases, 40%) because larger tumors
were preferred due to availability of redundant tissue aliquots
in the tissue bank. Consequently, metastasis in one or more
axillary lymph node was seen in 64 cases (61%). The distribu-
tion in accordance with grade was uniform, with a slight pre-
dominance of moderately and poorly differentiated tumors
(grade 1, 28%; grade 2, 35%; grade 3, 37%). The average
age of the patients was identical to their median age (59
years). The series contained 66 ductal carcinomas, 22 lobular
carcinomas, five atypical medullary carcinomas, two metaplas-
tic carcinomas, three mucinous carcinomas, two papillaryAvailable online http://breast-cancer-research.com/content/10/3/R48
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carcinomas, and five mixed ductal and lobular carcinomas. ER
expression was positive in 85 cases (81%) and progesterone
receptor expression was positive in 81 cases (77%). Initial
screening for overexpression of HER2/neu by immunohisto-
chemistry identified 20 cases (19%) with strong membrane
staining (2+ or 3+). Gene amplification was subsequently val-
idated using fluorescence in situ hybridization in 14 of these
cases (13%).
Sample processing
The lumpectomy or mastectomy resection specimens were
received within 20 minutes of surgical removal and were
immediately evaluated by a pathologist. Tissue pieces of
approximately 3 mm × 3 mm × 8 mm were cut from redundant
tumor tissue after standard surgicopathological processing,
were snap-frozen in liquid nitrogen and were stored at -80°C.
All samples analyzed were stored for no longer than 2 years,
and were thawed once immediately before analysis using
SELDI-TOF MS in January 2006.
The tissue microarrays were constructed from routinely pre-
pared formalin-fixed paraffin-embedded tissue blocks taken in
parallel, using manual tissue arrayer TA1 (A Fintajsl, Czech
Republic). Tissue lysis was performed in guanidine buffer (100
mM phosphate buffer, pH 6.6; 6 M guanidine–HCl, 1% Triton
X-100) [23] with vigorous shaking for 1 hour at room temper-
ature followed by centrifugation for 30 minutes at 14,000 × g.
The total protein concentration was measured by Bradford
assay (Bio-Rad, Hercules, CA, USA), and the lysates were
aliquoted and stored at -80°C.
SELDI-TOF MS analysis
A pilot study was performed using IMAC30 chips, CM10 (with
cation exchange surface, buffer pH 4) and Q10 arrays (with
anion exchange surface, buffer pH 9). The final selection was
made on the basis of number of peaks detected in spectra
(IMAC30 and CM10 displayed a similar number of peaks,
Q10 displayed about one-half the number of peaks), on the
overall intensity of spectra (the IMAC30 has higher intensity
than CM10) and in agreement with published results of other
studies previously performed with breast tissue lysates using
IMAC30 arrays [17,21].
Table 1
Antibodies and probes used
Immunohistochemistry Manufacturer, clone Antigen retrieval Dilution Evaluation
Estrogen receptor alpha Lab Vision, SP1 0.01 M citrate NaOH, pH 
6.0
1:4,000 Threshold at 5% positive 
nuclei
Estrogen receptor beta Novocastra, EMR02 0.001 M EDTA-NaOH, pH 
8.0
1:100 Threshold at 5% positive 
nuclei
Progesterone receptor Lab Vision, SP2 0.01 M citrate NaOH, pH 
6.0




Dako, polyclonal 0.01 M citrate NaOH, pH 
6.0
1:200 0 - 1 + -2 + 3 + according 
to DAKO manual
Cytokeratin 5/6 Dako, D5/6 B4 0.001 M EDTA-NaOH, pH 
8.0
1:200 Threshold at 1% positive 
tumor cells
Cytokeratin 14 Novocastra, LL002 0.01 M citrate NaOH, pH 
6.0




Lab Vision, SP4 0.001 M EDTA-NaOH, pH 
8.0
1:800 Threshold at 5% positive 
nuclei
Mucin 1 Novocastra, MA695 0.001 M EDTA-NaOH, pH 
8.0
1:800 0 negative; 1, 1% to 50%; 
2, >50% tumor cells 
positive
Gross cystic fluid protein Novocastra, 23A3 0.001 M EDTA-NaOH, pH 
8.0
1:800 Threshold at 1% positive 
tumor cells
In situ hybridization Probe Protocol Evaluation
HER2/neu amplification Abbott PathVysion HER2 
DNA Probe Kit
Manufacturer's instructions Locus-specific signal to 
centromere signal ratio 
>2.0 considered amplified
Cyclin D1 amplification Abbott Vysis LSI Cyclin 
D1/CEP11
Manufacturer's instructions Locus-specific signal to 
centromere signal ratio 
>2.0 considered amplified
EDTA, ethylenediamine tetraacetic acid. Lab Vision (Thermo Fisher Scientific, Fremont CA, USA); Novocastra (Leica Microsystems, Wetzlar, 
Germany); Dako (Glostrup, Denmark); Abbott (Abbott Park, IL, USA).Breast Cancer Research    Vol 10 No 3    Brozkova et al.
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Protein profiling was performed on IMAC30 ProteinChip
Arrays (Bio-Rad) preactivated with copper and following the
manufacturer's instructions. A total of 20 μg protein was
applied to each spot, diluted 16 times in binding buffer. Finally,
2 × 1 μl sinapinic acid (saturated solution in 0.5% trifluoroace-
tic acid/50% acetonitrile) was applied. Chips were analyzed
on the ProteinChip Reader Model PBS IIc (Bio-Rad) in posi-
tive linear mode. Each sample was applied randomly and
measured twice. The laser intensity was set at 190 (in relative
units, with a range from 0 to 300), detector sensitivity at 5 (in
relative units, within the range of 1 to 10) and focus mass at
10 kDa to obtain mass data within the range of 3 to 100 kDa.
Each spot (divided into 100 positions) was measured from
positions 20 to 80 with steps of four positions. At each single
position, 13 transients resulting in 195 shots per spot were
measured.
All spectra were collected together into one experimental file.
Two spectra, which did not contain any peaks in consequence
of an array processing error, were eliminated. To ensure the
mass accuracy, all spectra were calibrated using external
mass standards: hirudin BHVK (6,964 Da), equine myoglobin
(cardiac, 16,951.5 Da), and bovine carbonic anhydrase RBC
(29,023.7 Da). To avoid interspectra variability, the intensities
of all spectra were normalized to the total ion current using an
external normalization coefficient (Ciphergen ProteinChip soft-
ware 3.2.1; Bio-Rad, Hercules, CA, USA). The value of this
coefficient was set at 0.09 (the total ion current value of the
least intensive spectrum) to keep the normalization factor of all
spectra no higher than one. The normalization process takes
the total ion current used for all the spots, averages the inten-
sity and adjusts the intensity scales for all the spots, enabling
one to display all the data on the same scale. The baseline ion
current values were automatically subtracted to calculate the
total ion current measurements; the spectra were normalized
in a range from 2 to 100 kDa. Molecular masses below 2 kDa
were not analyzed due to masking of peptide signals by peaks
from the sinapinic acid matrix.
Finally, we performed internal mass calibration using an
endogenous peak at 15,841 Da that appears in all the
selected spectra. This step adjusts the mass scaling (x axis) of
the entire spectrum on the basis of the naturally occurring
sample peaks. External calibration was performed once before
the study and was controlled during the study period without
any significant changes. Next, peak clustering was calculated
with Biomarker Wizard software (Bio-Rad, Hercules, CA,
USA) with a signal/noise ratio >5 and 5% minimum spectra
detection in the first pass, and then peaks with a signal/noise
ratio >3 in a cluster mass window of range 0.3% were added;
the valley depth was set at three times the noise. Peak intensi-
ties from duplicate samples were then averaged. Ultimately, a
final set of 130 identified peak clusters was used for analysis.
Statistical analysis of SELDI-TOF MS mass spectra
The dataset comprised protein expression profiles of 105
samples, each represented by 130 peaks. Together with
expression profiles, additional information about 17 clinico-
pathological variables was available. We performed unsuper-
vised clustering of carcinoma cases according to their protein
expression profiles, and we tested distribution of categories of
clinical and molecular variables in these groups.
To reveal subgroups of peaks and patients, the dataset was
analyzed by hierarchical clustering with the Ward method of
linkage of clusters [24] and the distance measure was derived
from the Spearman correlation matrix. The Ward method
attempts to minimize the sum of squares of any two (hypothet-
ical) clusters that can be formed at each step. The distance
measure was derived as absolute value of (Spearman correla-
tion-1). The maximum distance of two therefore represents a
Spearman correlation of -1, and the minimal distance of zero
represents a Spearman correlation of 1.
For analysis of the relationship between categorical clinico-
pathological variables and the different groups of women (as
estimated by cluster analysis), a Fisher exact test (for 2 × 2
contingency tables) and a maximum likelihood chi-square test
(for n × n contingency tables) were performed. Kruskall–Wal-
lis analysis of variance was used to compare the age distribu-
tion between groups. All hypotheses were tested at
significance level α = 0.05. To avoid a multiple testing prob-
lem, the α value was adjusted by a Bonferroni correction for
the appropriate number of clinicopathological variables, thus
obtaining α = 0.05/17 = 0.0029.
The parameters were tested against three main clusters (A, B,
C) and against five smaller clusters (I, I, II, IV, V). For some
parameters, dividing patients into five clusters resulted in rela-
tively low numbers in some categories; it is therefore not pos-
sible to draw any general conclusions on the results of these
parameters, but these P values are included for informative
purposes.
Multivariate analysis was performed using R statistical soft-
ware version 2.4.0 (R Development Core Team, R foundation
for statistical computing, Vienna, Austria). Statistical testing
was performed using the STATISTICA 7.1 software (StatSoft
Inc., Tulsa, OK, USA).
Protein identification
Tissue lysate was preseparated using four IMAC Spin Col-
umns (Bio-Rad Laboratories, Hercules, CA, USA) (1 mg pro-
tein lysate for each column) according to the manufacturer's
instructions, with 2 × 100 μl of 250 mM imidazole in binding
buffer as the elution buffer. Eluted protein mixtures were dia-
lyzed overnight against 40 mM Tris–HCl buffer (pH 7.0), com-
bined and dried under vacuum. The pellet of IMAC
preseparated proteins was resolubilized in 20 μl reducingAvailable online http://breast-cancer-research.com/content/10/3/R48
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sample buffer A [25] for tricine SDS-PAGE (see below), or in
80 μl sample solution B containing 10% acetonitrile in 0.1%
trifluoroacetic acid for further reverse phase-liquid
chromatography fractionation. This fractionation was per-
formed on an Agilent HP 1100 HPLC system (Agilent Tech-
nologies, Santa Clara, CA, USA) using a Discovery Bio Wide
Pore C18 column (10 cm × 2.1 mm, 5 μm particle size; Sigma-
Aldrich Corp., St. Louis, MO, USA) with a 2 cm guard precol-
umn. Separations were performed at 35°C, and mobile phase
A consisted of 0.1% trifluoroacetic acid in water while mobile
phase B consisted of 0.1% trifluoroacetic acid in acetonitrile.
The proteins were eluted using a linear gradient of mobile
phase B (0% to 100% B in 25 minutes) followed by elution
using 100% mobile phase B in 10 minutes; the flow rate was
100  μl/min (following the method of Moshkovskii and col-
leagues [25], with several modifications). The collected frac-
tions (60 μl each) were dried under vacuum and resolubilized
in 20 μl sample solution B for protein profile determination on
SELDI-TOF MS (2 μl each resolubilized fraction was analyzed
on NP20 chips). Selected fractions containing the protein(s)
of interest were mixed together and dried under vacuum. The
proteins were redissolved in 20 μl sample buffer A, heated
(95°C/3 minutes), centrifuged (16,000 × g/20 minutes/4°C)
and separated using tricine SDS-PAGE on PROTEAN II XL
apparatus (Bio-Rad) according to Schagger [26].
The gel – consisting of 4% sample gel, 10% spacer gel and
16% separation gel – was stained using colloidal Commassie
Blue. The bands with appropriate molecular weight were cut
out and digested by trypsin according to Havlasova and col-
leagues [27]. Mass spectra were acquired using a 4800
MALDI TOF/TOF™ spectrometer (Applied Biosystems, Foster
City, CA, USA) in both positive reflectron and MS/MS modes.
GPS Explorer™ software (version 3.6; Applied Biosystems,
Foster City, CA, USA) was used for the evaluation of mass
spectra and the identification of proteins.
Results
IMAC 30 (immobilized metal affinity capture) ProteinChip
arrays were used to analyze tissue lysates from 105 breast
cancer patients. After data processing by Biomarker Wizard
software, a total of 130 peaks were selected. Information
about the peaks is presented in Additional file 1. The normal-
ized linear intensities of peaks analyzed by hierarchical cluster-
ing revealed subgroups of peaks and of patients. The
graphical representation of Spearman correlation matrix of
peaks is shown in Figure 1. These data clearly demonstrate
the groups of peaks that are highly positively correlated, indi-
cating coexpression of these peaks in individual tumors. The
hierarchical clustering combines peaks into two, three, or six
potential groups, respectively, according to their level of posi-
tive correlation. In each of these categories we can find groups
of adjacent correlated peaks, as apparent in Figure 1. The
highest correlation can be found between peaks from 80 to
82, peaks from 99 to 105, 117 and 118, and peaks from 121
to 124, which form the first group of six categorizations.
Descriptive statistics for peaks classified into the six groups
are summarized in Table 2. Note that the groups are listed
according to decreasing minimal correlation within the group.
Using the Spearman correlation matrix to derive the distance
matrix for hierarchical clustering, the categorization of patients
was most strongly affected by groups of highly correlated
peaks.
Figure 2 shows the result of hierarchical clustering in the form
of a heatmap of values of peaks, where rows represent individ-
ual patients and each column represents one of the 130 peaks
used for the analysis. Unsupervised hierarchical clustering of
patients (Figure 2) revealed two, three and five potential
groups. Categorization into five groups of patients (details in
Additional file 2) and into six groups of peaks (details in Addi-
tional file 3) shows that, for the first and the second groups of
patients, high values of the fifth and sixth groups of peaks are
characteristic, while the first group reveals also higher values
Table 2
Descriptive statistics of groups of peaks as revealed by hierarchical clustering
Categorization Spearman correlation between peaks in the category
N Median Mean Minimum Maximum % < 0.1 % 0.1 to 0.5 % > 0.5
1 1 1 120 0.76 0.74 0.35 0.99 0.0 8.3 91.7
2 153 0.44 0.44 0.02 0.83 0.0 60.1 39.9
2 2 3 120 0.34 0.34 -0.14 0.94 0.0 50.1 33.2
4 378 0.26 0.28 -0.26 0.92 5.6 74.6 19.8
3 5 210 0.43 0.38 -0.29 0.96 5.2 57.6 37.1
6 465 0.29 0.28 -0.42 0.90 11.0 68.0 21.1
% < 0.1, percentage of correlations with value smaller than 0.1; % 0.1 to 0.5, percentage of correlations in the interval 0.1 to 0.5; % > 0.5, 
percentage of correlations with values greater than 0.5. Categories are ordered according to decreasing minimal correlation in the group. N, 
number of correlations between peaks in the category: N = (number of peaks in the category2 - number of peaks in the category)/2).Breast Cancer Research    Vol 10 No 3    Brozkova et al.
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in the first cluster of peaks. The third group of patients is char-
acterized by higher values in the third cluster of peaks, espe-
cially peaks between 1 and 9 and between peaks 23 and 40.
The fourth group of patients reveals very high values in the first
cluster of peaks, and the fifth group of patients is mainly deter-
mined by high values in the second cluster of peaks.
The relative frequencies of selected clinicopathological
parameters are illustrated in Figure 3 and a complete distribu-
tion of clinical variables and molecular markers within the
groups of patients is presented in Table 3. The 105 cases are
separated into three main clusters (A, B, C) or into five smaller
clusters (I to V), significantly associated with tumor type, ER
status and nuclear grade. The older patients with tumors
expressing hormonal receptors and a high level of mucin 1
tend to group into clusters I to III (or A and B), while the carci-
nomas of younger patients exhibiting triple negative (that is,
ER, progesterone receptor, HER2/neu) phenotype, high
nuclear grade and basal cytokeratin 5/6 and/or cytokeratin 14
locate more often to cluster IV and especially cluster V (or C).
Clusters I and III differ in relative frequency of lobular carcino-
mas (predominate in cluster I) and ductal carcinomas (pre-
dominate in cluster III), otherwise sharing similar
characteristics (ER-positive, low grade, older patients). Clus-
ter II is characterized with higher nuclear and tumor grade if
compared with adjacent clusters I and III, and contains one-
half of the 14 cases exhibiting HER2/neu gene amplification.
Cluster IV exhibits some transitional characteristics from
clusters I to III to cluster V, where the high-grade, triple-nega-
tive carcinomas with low expression of mucin 1 and gross
cystic fluid protein clearly predominate. Cyclin D1 coding gene
amplification is randomly distributed except in cluster V. Cyclin
D1 protein expression is distributed similarly to ER, and the
same applies for ERβ. The distribution of lymph node metas-
tases does not exhibit a specific relationship with clustering.
Clustering of patients into five groups was determined by the
expression profile of all 130 peaks. To identify these peaks we
separated the IMAC binding proteins either by HPLC and tri-
cine SDS-PAGE or directly using tricine SDS-PAGE with sub-
sequent MS/MS identification. For the final identification we
extracted four gel bands with identical SELDI-TOF MS and tri-
cine gel molecular masses (7,706 Da, 17,599 Da, 27,152 Da
and 33,327 Da corresponding to peaks 81, 107, 114 and
119). Using MS/MS analysis of samples separated by reverse
phase-liquid chromatography prior to tricine SDS-PAGE, we
identified a peak with molecular mass of 33 kDa as annexin 5
(accession number NP 001145). MS/MS analysis of IMAC
binding proteins directly separated by tricine SDS-PAGE lead
to identification of a peak with mass 27 kDa as heat shock pro-
tein 27 (hsp27) (accession number AAA62175). Both pro-
teins were identified with a protein score confidence interval of
100%. The result of identification of two remaining peaks was
not successful.
Figure 1
Graphical representation of Spearman correlation matrix of 130 sur- face-enhanced laser desorption/ionization time-of-flight mass spec- trometry peaks Graphical representation of Spearman correlation matrix of 130 sur-
face-enhanced laser desorption/ionization time-of-flight mass spec-
trometry peaks. Red color intensity, positive correlation; green color 
intensity, negative correlation.
Figure 2
Result of hierarchical clustering in the form of a heat map of peak  values Result of hierarchical clustering in the form of a heat map of peak val-
ues. Rows represent 105 individual patients and columns represent 
130 peaks used for the analysis. The value of the peak is indicated by 
the color intensity. Unsupervised hierarchical clustering revealed two 
(not labeled), three (labeled A, B, C), five (labeled I to V) and six 
(labeled 1 to 6) groups of patients.Available online http://breast-cancer-research.com/content/10/3/R48
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Table 3
Distribution of clinicopathological variables within groups of patients as revealed by hierarchical clustering
Clusters of patientsa
AB C
II I I I I I V V
Distribution Count 27 23 24 22 9
Age Mean 64.3 58.3 59.6 55.7 55.4
p5 = 0.235, p3 = 0.212, N =  1 0 5 M e d i a n 6 45 56 05 74 9
Tumor type Lobular and mixed ductal/lobular 12 5 5 4 1
p5 = 0.040*, p3 = 0.021*, N = 105 Ductal not otherwise specified 15 17 16 14 4
Mucinous, papillary 0 0 2 2 1
Medullary, spindle cell 0 1 1 2 3
Lymph node metastases Absent 10 8 6 12 5
p5 = 0.240, p3 = 0.065, N = 105 Present 17 15 18 10 4
Maximal tumor diameter <20 mm (pT1) 6 11 12 13 0
p5 = 0.001*, p3 = 0.408, N = 105 > 20 mm (pT2, pT3) 21 12 12 9 9
Tumor grade Grade 1 8 5 7 7 2
p5 = 0.138, p3 = 0.199, N = 105 Grade 2 14 7 10 5 1
Grade 3 5 11 7 10 6
Nuclear grade Grade 1 6 2 2 6 2
p5 < 0.001**, p3 < 0.001**, N = 105 Grade 2 17 15 20 9 0
G r a d e  3 46277
Estrogen receptor alpha Positive 25 18 24 15 3
p5 < 0.001**, p3 < 0.001**, N =  1 0 5 N e g a t i v e 25076
Estrogen receptor beta Positive 20 11 13 8 3
p5 = 0.078, p3 = 0.030*, N = 99 Negative 7 8 10 13 6
Progesterone receptor Positive 23 16 24 14 4
p5 < 0.001**, p3 < 0.001**, N =  1 0 5 N e g a t i v e 47085
HER2 amplification by fluorescence in situ hybridization Absent 25 16 22 19 9
p5 = 0.071, p3 = 0.398, N =  1 0 5 P r e s e n t 27230
HER2/neu by immunohistochemistry 3+ 2 5 2 3 0
p5 = 0.008*, p3 = 0. 046*, N = 105 2+ 0 3 3 2 0
1+ 10 10 7 2 1
0 15 5 12 15 8
Cytokeratin 5/6 or cytokeratin 14 Positive 2 3 0 4 3
p5 = 0.035*, p3 = 0.010*, N = 99 Negative 24 18 23 16 6Breast Cancer Research    Vol 10 No 3    Brozkova et al.
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Discussion
The goal of expression profiling of human tumors is to provide
information that can assist with tumor diagnosis or classifica-
tion, or can provide prognostic information. To be of value,
such data must improve on the clinicopathological assess-
ments already used. Gene expression profiling has shown its
worth in these respects in recent years, and in breast cancer
has provided alternative classification systems that appear val-
uable in clinical practice. Protein expression profiling has also
been useful in studies of human tumors and has often been
used to identify serum biomarkers that aid disease monitoring
and the therapeutic response. In the present article we ana-
lyzed protein profiles in breast cancers and evaluated the
potential for this approach to provide clinically useful classifi-
cations of this heterogeneous disease.
The protein expression profiles of tumors obtained in our
study, consisting of as little as 130 substantially intercorre-
lated peaks, must certainly represent only a small fraction of
tumor nature. The diversity in profiles reflects necessarily both
biological diversity and methodological factors, including vari-
able tumor/stroma ratios. Nonetheless, our data clearly show
T r i p l e - n e g a t i v e  p h e n o t y p e Y e s 01056
p5 < 0.001**, p3 < 0.001**, N =  1 0 5 N o 2 72 22 41 73
Cyclin D1 amplification by fluorescence in situ hybridization Absent 22 21 18 17 9
p5 = 0.354, p3 = 0.875, N =  1 0 2 P r e s e n t 52440
Cyclin D1 by immunohistochemistry Positive 26 17 21 18 4
p5 = 0.001**, p3 = 0.111, N =  1 0 1 N e g a t i v e 05235
Mucin 1 2+ 17 12 21 9 1
p5 = 0.001**, p3 < 0.001**, N =  1 0 2 1 + 91 0 277
0 10051
Gross cystic fluid protein Positive 10 10 13 9 2
p5 = 0.572, p3 = 0.440, N = 98 Negative 15 13 10 10 6
p5 values, results of statistical testing within five groups of patients and are rather informative because of the small number of patients in each 
group; p3 values, result of statistical testing within three groups of patients. *P values significant at the 5% significance level. **P values significant 
at a significance level adjusted by Bonferroni correction (0.05/17 = 0.0029). For some parameters evaluated in tissue microarrays, information 
was not available in all patients. aA to C, three clusters; I to V, five clusters.
Table 3 (Continued)
Distribution of clinicopathological variables within groups of patients as revealed by hierarchical clustering
Figure 3
Distribution of selected clinicopathological parameters within the cluster tree of patients Distribution of selected clinicopathological parameters within the cluster tree of patients. Each square label represents a case. ER, estrogen recep-
tor; MUC1, mucin 1.Available online http://breast-cancer-research.com/content/10/3/R48
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that this approach provides robust, statistically significant
groupings of patients that are related to the recently described
classifications based on cDNA expression profiling. Correlat-
ing protein expression patterns to tumor morphology,
established biomarkers and clinical outcomes is therefore a
key issue of high-throughput studies to discover peaks that
merit further investigation.
The categories of patients identified by hierarchical clustering
of SELDI-TOF MS peaks resemble the recently adopted clas-
sifications of breast carcinomas based on gene expression
profiling [2]. In this study the first subgroup, so-called luminal
subtypes (A and B), makes up the hormone receptor-express-
ing breast cancer and has expression patterns reminiscent of
the luminal epithelial component of the breast (including lumi-
nal cytokeratin 8/18 and cyclin D1 genes). The second sub-
group is called the HER2/neu  subtype, but should not be
confused with HER2/neu-positive tumors identified by
immunohistochemistry or fluorescence in situ hybridization
because not all clinically HER2/neu-positive tumors show the
RNA expression changes that define this subtype. Tumors that
do not express hormone receptors are included in this group.
The last group of breast cancers distinguished by gene
expression profiling is called basal-like breast cancer and
lacks expression of ER, has low expression of HER2/neu, has
strong expression of basal cytokeratins 5, 6 and 14, and
expresses high levels of proliferation-related genes [4-6,28].
Our groups I and III exhibit striking similarity to luminal A
tumors, group II resembles luminal B carcinomas, while groups
IV and V resemble HER2/neu subtype and basal carcinomas.
On the other hand, we found no significant relationship of our
tumor clusters to the presence of lymph node metastases.
Regarding the potential prognostic significance of our data,
the follow up of the patients is not yet long enough to allow a
valuable analysis.
Although controversial, it may be acceptable to use a pro-
teomic polypeptide profile consisting of as yet unsequenced
peptides for the diagnosis of disease and to predict the risk of
disease development and progression and/or the efficacy of
treatment – if it has proven its value in blinded multicenter and
repeated studies, as recently pointed out [29]. For a fuller
understanding of disease processes and to simplify the inves-
tigative procedures, it may also be useful to identify the
biomarkers. We were able to identify peak 114 from the fifth
peak cluster group with mass 27,152 Da as hsp27. This pro-
tein is a molecular chaperone, participating in cell homeostasis
under stress conditions, and is associated with resistance of
tumors to chemotherapeutics, radiation and hyperthermia
[30].
High intensities of all peaks occurring in fifth and sixth peak
cluster groups, including the hsp27 peak, classify patients into
subcohorts I and III corresponding to luminal A subtype of
tumors with high expression of ER. This finding is in agreement
with Ciocca and colleagues, who showed correlation of high
levels of hsp27 with ER expression [31]. Recent studies
revealed the correlation of hsp27 phosphorylation status (that
also increases protein binding on the IMAC surface) with
HER2/neu and lymph node positivity in breast cancer [32].
We could also identify the peak at 33,327 Da from the sixth
peak cluster group as annexin 5. The annexin family has been
linked to inhibition of phospholipase activity, exocytosis and
endocytosis, signal transduction, organization of the extracel-
lular matrix, resistance to reactive oxygen species and DNA
replication [33]. Annexin 5 normally forms a shield around cer-
tain phospholipid molecules that blocks their entry into coag-
ulation reactions [34]. The role of annexin 5 in breast cancer,
however, is elusive.
Our methodological approach of unsupervised hierarchical
clustering helped overcome some of the complexities of
SELDI-TOF MS to yield biologically meaningful and interpret-
able data. In the present study we demonstrated that, using
the whole protein spectra, we were able to cluster our patients
into subcohorts paralleling classification based on DNA micro-
array profiling data.
Conclusion
Our results show that SELDI-TOF MS protein profiling distin-
guishes between different groups of primary human breast
cancers and produces a similar clustering of tumors as cDNA
expression profiles. This fact testifies to the validity of the
SELDI-TOF MS proteomic approach in these types of study.
As SELDI-TOF MS provides different information compared
with cDNA expression profiles, the results suggest its poten-
tial to supplement and expand our knowledge of breast carci-
nomas. The identification of proteins belonging to the
interesting peaks followed by validation by immunohistochem-
istry is an essential task for future studies. Although many
parameters have been explored in relation to breast cancer
biology and outcome, the ability to classify tumors into distinct
subclasses by identifying representative protein expression
patterns improves our understanding of cancer biology and
provides the potential for more precise clinicopathological
phenotyping.
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